

DRAFT AGENDA
MTPPI Technical Advisory Committee (TAC)
on Human Recombinant Erythropoietin Utilization
in the Medicare Patient Populations
August 15th, 9:30 a.m. to 3:30 p.m.
Calvert I & II Conference Room, Residence Inn Bethesda
Bethesda, Maryland

- 9:30 a.m. Welcome and TAC Objectives, *John Sadler/Dennis Cotter*
- 9:35 a.m. Review of Nov 16, 2005 TAC Draft Minutes, *John Sadler/Dennis Cotter*
- 9:40 a.m. Update of CMS EPO Activities, *Kim Long/Beth Koller/Maria Ciccanti*
- 9:45 a.m. Update of NIH/NIDDK EPO Research Activities, *Paul Eggers/Daniel Wright*
- 9:50 a.m. Review of Invited Guests' EPO Research Activities
- 10:15 a.m. Review of MTPPI Published ESRD/EPO Research, *Mae Thamer/Yi Zhang*
- 10:30 a.m. MTPPI planned presentation for FDA/CDER's Sept 11th Cardiorenal Advisory Committee meeting, *Mae Thamer/Yi Zhang*
- Practice patterns - EPO dosing by provider status
 - Effectiveness - EPO dose (exposure) - hematocrit response relationship
 - Safety - EPO dose (exposure) - mortality relationship
 - Future research
- 11:30 a.m. Discussion of issue profiles:
- Implications of survival research findings
 - Design of anemia management strategies
 - Predictors of early mortality among CKD population
- 12:00 noon Lunch (served in conference room)
- 12:30 p.m. Continued discussion of issue profiles
- 1:30 p.m. Update of DVA Boston EPO Research Activities and Hematocrit Variability
James Kaufman
- 2:00 p.m. Discussion of the applicability of MSM methods to determine payment adjustment and the impact of EPO bundling on independent dialysis centers (Small Group/Independent Facility Panel: 4 to 5 invited guest representatives led by *John Sadler*)
- 3:30 p.m. Adjournment